Supplemental Information A Cytoplasmic ATM-TRAF6 · PDF fileSupplemental Information A...
Transcript of Supplemental Information A Cytoplasmic ATM-TRAF6 · PDF fileSupplemental Information A...
Molecular Cell, Volume 40
Supplemental Information
A Cytoplasmic ATM-TRAF6-cIAP1 Module Links Nuclear DNA Damage Signaling to Ubiquitin-Mediated NF-κB Activation Michael Hinz, Michael Stilmann, Seda Çöl Arslan, Kum Kum Khanna, Gunnar Dittmar, and Claus Scheidereit Inventory of Supplemental Information Hinz et al.
Figure S1 and S2 are related to Figure 1 Figure S1 shows, that ATM translocation is also triggered by etoposide and is independent of the components of the PARP-1 signalosome. Figure S2 demonstrates selective calcium dependency of DNA damage induced NF-κB activation and absence of early DNA damage induced alterations of calcium concentrations. Figure S3 is related to Figures 2 and 5 Figure S3 summarizes the results of an siRNA screen for pathway components required for DNA damage induced NF-κB activation. Figure S4 is related to Figure 4 Figure S4 describes the requirement of TAK1 for DNA damage induced NF-κB activation. Moreover it shows that TAK1 activation does not depend on PARP-1 or PIASy. Figure S5 is related to Figure 5 Figure S5 shows a longer exposure of figure 5B and calcium dependency of IKKgamma monoubiquitination Figure S6 is related to Figure 5 Figure S6 shows that the association of TRAF6 with cIAP1 depends on the RING domain in TRAF6. Figure S7 is related to Figure 6 Figure S7 shows that IKKγ monoubiquitination is induced by TNFα.
Figure S1. DNA damage induced ATM translocation is independent of the PARP-1 signalosome, related to Figure 1. (A) HepG2 cells were treated with etoposide (10 µM) for 30 min and fractionated. Crude cytoplasmic (CE) and nuclear extracts (NE) were analyzed by western blotting with ATM, P-ATM, PARP-1 or tubulin antibodies, respectively. (B) HepG2 cells were transfected with control siRNA or siRNA against PARP-1 or PIASy. Cells were treated with IR for 45 min, as indicated, and fractionated. Membranes and nuclear extracts (NE) were analyzed by western blotting with ATM, P-ATM, PARP-1 or PIASy antibodies, respectively. The membrane fraction was additionally analyzed with an IKKγ antibody.
ATM
P-ATM
PARP-1
PIASy
IKKγ
- -- -- - -- + ++ ++ + ++ IREto
siContr
ol
siContr
ol
siPARP-1
siPARP-1
siPIASy
siPIASy
membranes NE
270-
270-
170-
170-
130-130-
72-
55-
55-
ATM
P-ATM
PARP-1
Tubulin
CE NE
BA
Figure S2. DNA damage- but not TNFα-induced NF-κB activation is calcium dependent, related to Figure 1. (A) HeLa cells were pre-incubated with solvent alone (DMSO) or with BAPTA for 60 min and treated with IR for the indicated time. WCE were monitored for NF-κB activation by EMSA. Free DNA probe is not shown (B) Cells were treated as in (A). Crude cytoplasmic (CE) or nuclear (NE) fractions were analyzed by western blotting with antibodies against IκBα, p65, PARP-1 or p105. (C) Cells were pre-incubated with BAPTA for 60 min and
A B
C D
DMSO DMSO
DMSODMSO
DMSO
DMSO
BAPTA BAPTA
BAPTA
BAPTA
BAPTA
BAPTA
0 0 00 0 01 1 11 1 12 2 22 2 2h post-IR h post-IR
NF- Bκ
NF- Bκ
- - -- - -+ + ++ + +TNF (15 min)α TNF (15 min)α
CE
CE
NE
NE
I Bκ α
I Bκ α
p65
p65
PARP-1
p105
p105
43-
43-
34-
34-
130-
130-
130-
72-
72-
IKKγ55-
*
*
9
11
10
12
13
min upon treatment 0 20 40 60
DMSOATP
9
11
10
12
Cal
cium
con
cent
ratio
nar
bita
ry u
nits
(x10
00)
Cal
cium
con
cent
ratio
nar
bita
ry u
nits
(x10
00)
min upon treatment 0 20 40 60
DMSOEtoE
treated with TNFα for 15 min. WCE were monitored for NF-κB activation by EMSA as in (A). (D) Cells were treated as in (C). Crude cytoplasmic (CE) or nuclear (NE) fractions were analyzed by western blotting with antibodies against IκBα, p65, p105 and IKKγ. (E) Changes in intracellular Ca2+ concentration were assessed in WT MEFs upon treatment with 100 µM etoposide (left panel) or with 1 mM ATP as a positive control (right panel). As a negative control the solvent DMSO was applied in each experiment. The fluorescence measurements were performed employing Fluo-4 NW Calcium Assay Kit (Invitrogen) and Mithras LB 940 plate reader (Berthold Technologies).
Figure S3. RNAi based NF-κB pathway analysis, related to Figures 2 and 5. (A) Cells were transfected with siRNAs against NF-κB signaling proteins as indicated. WCE were monitored for NF-κB activation by EMSA. “+” transfection of two different siRNAs significantly reduced DNA damage induced NF-κB activation, “-“ no reduction, “n.d.” not determined. (B) HepG2 cells were transfected with siRNAs against RIP-1. Cells were treated with IR for 2 h. WCE were monitored for NF-κB activation (EMSA) and immunoblotted for RIP-1 and PARP-1, respectively. (C) HepG2 cells were transfected with control siRNA or siRNA against cIAP1 and treated with IR for 2 h. WCE were monitored for NF-κB activation (EMSA) and cIAP1 expression (WB).
RNAi based NF- B pathway analysis*κ
HeLa 293HepG2
* readout: EMSA
cIAP1 + n.d.+
Ubc13 ++ +
TAK1 ++ +
TAB2 ++ +
TRAF6 + + +
MALT1 n.d. - -
BCL10 n.d. - -
TRAF2 - - -
RIP1 - - -
TAB1 - - -
- + ++UT UT
IRsiR
IP1_
1
siRIP
1-2
NF- Bκ
72-
EMSA
WB
130-
RIP1
PARP-1
A
B
EMSA
WB
72-
55-
55-XIAP
cIAP-1
NF- Bκ
IR
sicIAP1-1
siContr
ol
- + +
C
Figure S4. TAK1 requirement for DNA damage induced NF-κB activation, related to Figure 4. (A) HepG2 cells were transfected with control siRNAs or siRNAs against TAK1. Cells were treated with IR (10 Gy) for 1 h. Cells were divided and WCE were monitored for NF-κB activation (EMSA), while cytoplasmic extracts were immunoblotted for P-IKK, IKKβ, P-TAK1 and TAK1. (B) HeLa cells were transfected with control siRNAs or siRNAs against TAK1. Cells were treated with IR (10 Gy) for 1 h. Lysates were immunoprecipitated with IKKγ and analyzed for IKK kinase activity. Lysates were immunoblotted for TAK1 and IKKγ. (C) and (D) HepG2 cells were transfected with control siRNA or siRNAs against PARP-1 (C) or PIASy (D) and processed as in (A). Immunoblotting was performed with anti-P-TAK1, anti-TAK1, anti PARP-1 (C) or anti-PIASy (D). (E) HepG2 cells were treated with IR and fractionated. Membranes and cytosol were analyzed by western blotting as indicated.
A
B
C
D
P-TAK1
P-TAK1TAK1
TAK1
TAK1
72-
72-
72-
72-
72-
72-
72-
72-
UT UT
UT
siTAK1_
1
siTAK1_
1
siPARP-1-
1
siTAK1_
2
siPARP-1-
2
siPIASy
siContr
ol
siRIP
1
siContr
ol
siContr
ol
siContr
ol
- -
-
--
+ + +
+
+
+ +
-
-
+ +
+
++
P-IKK
PARP-1
PIASy
IKKβ
P-TAK1
TAK1
EMSA
EMSA
EMSA
WB
WB
WB
WB
IR IR
IR
IR
95-
95-
130-
*
*
*
GST-I Bas1-53)
κ α(
IKKγ
KA
55-
membranes cytosol
0 0 min post-IR
72- TAK1
10 1045 45
E
55-
43-Tubulin
55-
72-TNFR
72- P-TAK1
TAB272-
55- TAB1
NF- Bκ
n.s.
NF- Bκ
n.s.
NF- Bκ
n.s.
Figure S5. DNA damage induced IKKγ monoubiquitination takes place in the cytoplasm, related to Figure 5. (A) Long exposure of the experiment in figure 5B. (B) HepG2 cells were pre-incubated with solvent alone (DMSO) or with BAPTA for 60 min, treated with IR for 45 min, lysed and immunoprecipitated with anti-IKKγ. Lysates and IP extracts were immunoblotted with IKKγ antibodies.
- -+ + IR
*55-
DMSO BAPTA
55-
minpost-IR00 2020 4040 6060
IP: IKKWB: IKK
γγ
IP: IKKWB: IKK
γγ
A BCE NE
*
Figure S6. DNA damage induces an interaction between TRAF6 and cIAP1, related to Figure 5. 293 cells, transfected with FLAG-TRAF6-WT or FLAG-TRAF6Δ, a deletion mutant lacking the RING domain, were either left untreated or exposed to IR for 40 min. Cytoplasmic extracts were immunoprecipitated with anti-FLAG. Lysate and IP extracts were immunoblotted with cIAP1 and TRAF6 antibodies.
0 00 040 40 40 40 time upon IR40 40
IP FLAG
IP FLAG
TRAF6
72 -
26 -
43 -
72 -
cont
rol
cont
rol
55 -
34 -
55 -
cIAP1
T6-WT T6-WTT6-Δ T6-Δ
Input
*
Figure S7. TNFα signaling induces IKKγ ubiquitination, related to Figure 6. HepG2 cells were treated with TNFα for the indicated time. Lysates were immunoprecipitated with IKKγ antibody and immunoblotted with antibodies against IKKγ and Ubiquitin (Ub).
0 3 5 10 15 0 3 5 10 15
Input IP: IKKγmin
TNFα
55-
55-
IKKγ
Ub
*
*
Supplemental Experimental Procedures
Cell culture
MEFs were maintained in Hepes-buffered Dulbecco's modified Eagle's medium-Glutamax-I
(Invitrogen) containing 4.5 g/l glucose, 10% fetal calf serum (PAA Gold) and supplemented with
100 U/ml penicillin/streptomycin. For plasmid transfection Transfectin (Biorad) was used.
HepG2 and 1.3E2 cells were grown in RPMI 1640, HeLa and 293 cells in DMEM, all
supplemented with 10 % fetal calf serum, 2 mM L-glutamine and 100 U/ml
penicillin/streptomycin. For 1.3E2 cells, 50 µM β-ME was added. For irradiation, cells were
exposed to 10 Gy (HeLa, 293, 1.3E2), 30 Gy (HepG2), 80 Gy (MEF) using an OB29 Irradiator
(STS Braunschweig).
Reagents
Human recombinant TNFα and BAPTA/AM were purchased from Alexis Corporation, ATM
inhibitor Ku55933 and camptothecine from Calbiochem and etoposide from Biomol. Western
blots and immunoprecipitations were performed with antibodies directed against ATM (Bethyl
Laboratories), phospho-ATM (4526, Cell Signal Technology or 600-401-398, Rockland), CDK4
(sc-601, Santa-Cruz Biotechnology), cIAP1 (AF8181, R&D Systems) or (Proteintech), Flag
(M2), GFP and HA (all Sigma), HA affinity matrix (Roche) IκBα (sc-371, Santa-Cruz
Biotechnology), Phospho-IκBα (9241, New England Biolabs), IKKα (556532, BD
Pharmingen), IKKβ (2684, Cell Signal Technology), IKKγ (BD Transduction Laboratories) or
(sc-8330, sc-8256, Santa-Cruz Biotechnology), P-IKK (2697, Cell Signal Technology), p105/p50
(sc-7178, Santa-Cruz Biotechnology), p65 (sc-109, Santa-Cruz Biotechnology), PARP-1 (sc-
8007, Santa-Cruz Biotechnology), PIASy (sc-30875, Santa-Cruz Biotechnology), RIP1 (551041,
BD Pharmingen), SUMO-1 (Zymed), TAB1 (sc-6053, Santa-Cruz Biotechnology), TAB2 (sc-
11850 or sc-11851, Santa-Cruz Biotechnology), TAK1 (sc-7162 or sc-7967, Santa-Cruz
Biotechnology), Phospo-TAK1, (4508, Cell Signal Technology), TRAF6 (sc-7221 and sc-33897,
Santa-Cruz Biotechnology), TNF-R (sc-7895, Santa-Cruz Biotechnology), Tubulin (2-28-33,
Sigma), Ubc13 (37-1100 Invitrogen) and Ubiquitin (clone FK2, Assay Designs or sc-8017 Santa-
Cruz Biotechnology). Mouse monoclonal (CII-10) and rabbit polyclonal (288) antibodies against
PARP-1 were described previously (Mortusewicz et al., 2007).
Plasmids
Plasmids pRK5TRAF6Δ (289–522), pcDNA3-Flag-IKKγ-WT and pEF-MALT1 were described
previously (Oeckinghaus et al., 2007; Tegethoff et al., 2003). Human IKKγ-WT was subcloned
into pcDNA3-HA vector. Murine IKKγ-WT was purchased from RZPD and cloned into pTracer.
QuickChange® Site-Directed Mutagenesis Kit (Stratagene) was used to generate mutant IKKγ
constructs, TRAF6-C70A and pEF-MALT1-2EA (E642/795A). TRAF6-C70A mutant protein is
defective in E3 ligase activity (Deng et al., 2000). MALT1-2EA mutant protein is defective in
TRAF6 binding and activation (Sun et al., 2004)). pEFUBC13-C87A (catalytic inactive mutant)
has been described (Deng et al., 2000). For construction of GFP-ATM 9 (2141-2428) and GFP-
ATM 9ΔT6 (2158-2428) DNA fragments were generated by PCR from the corresponding
bacterial expression construct, and cloned into pEGFP-C3 (Clontech Labatories Inc.).
Calcium measurements
Detection of changes in intracellular calcium concentration was performed using Fluo-4 NW
Calcium Assay Kit (Invitrogen) in WT MEFs according to manufacturer's instructions. Briefly,
3x104 MEF cells were plated per a well of a black 96-well plate (Nalge Nunc International) 24
hrs before the experiment. Cells were washed once with HBSS (20 mM Hepes) and loaded with
100 µl Fluo-4 AM solution for 20 min at 37°C. Subsequently the staining solution was removed
and after washing with HBSS, cells were tempered to 30°C for 10 min. For application of ATP
(1mM) or etoposide (100 µM) solutions and for the fluorescence measurement Mithras LB 940
plate reader (Berthold Technologies) was used. Fluorescence was measured for 1 sec with 485
nm excitation and 535 emission filter every 15 sec for a period of one hr after application of the
test solution.
siRNA sequences
The following target sequences (5’ to 3’) were used:
siATM-1 CCATGGAAGTGATGAGAAA
siATM-2 GGTAGAAGATTGTGTCAAA
siATM-3 GCAGAAACGUGCUUAGAAA
siBCL10-1 GTGCUGAAACUUAGAAAUA
siBCL10-2 GGACUAAAAUGUAGCAGUU
sicIAP1-1 GGCUUGAGGUGUUGGGAAU
sicIAP1-2 GGAUCCACCUCUAAGAAUA
siIKKγ: GGAAGAGCCAACUGUGUGA
siMALT1-1 GGAAGUGAAUGUUGGGAAA
siMALT1-2 GGAUGAAGUUGCAGAAGAU
siRIP1_1: CCACUAGUCUGACGGAUA
siRIP1_2: GCAAAGACCUUACGAGAAU
siPARP-1-1 AGCCUCCGCUCCUGAACAA
siPARP-1-2 GAUAGAGCGUGAAGGCGAA
siPIASy CCGAAUUAGUCCCACAGAA
siTAK1-1 GCCACAAAUGAUACUAUUA
siTAK1-2 UGGCUUAUCUUACACUGGA
siTAB1-1 CCACAGAGAACGAGGAUGA
siTAB1-2 GGGAUUACAAGGUUAAAUA
siTAB2-1 CAGCAUUAGUGAUGGACAA
siTAB2-2 GGUGCAUGUUACAGAAUAA
siTRAF2-1 AUACGAGAGCUGCCACGAA
siTRAF2-2 GGCCAGUCAACGACAUGAA
siTRAF6-1 CCAGCUCCUGUAGCGCUGUAACAAA
siTRAF6-2 CCACGAAGAGAUAAUGGAU
siUbc13-1 CUAGGCUAUAUGCCAUGAA
siUbc13-2 CAGUUCUGCUAUCGAUCCA
Supplemental References Deng, L., Wang, C., Spencer, E., Yang, L., Braun, A., You, J., Slaughter, C., Pickart, C., and Chen, Z. J. (2000). Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351-361. Mortusewicz, O., Ame, J. C., Schreiber, V., and Leonhardt, H. (2007). Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells. Nucleic Acids Res 35, 7665-7675. Oeckinghaus, A., Wegener, E., Welteke, V., Ferch, U., Arslan, S. C., Ruland, J., Scheidereit, C., and Krappmann, D. (2007). Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. Embo J 26, 4634-4645. Sun, L., Deng, L., Ea, C. K., Xia, Z. P., and Chen, Z. J. (2004). The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 14, 289-301. Tegethoff, S., Behlke, J., and Scheidereit, C. (2003). Tetrameric oligomerization of IkappaB kinase gamma (IKKgamma) is obligatory for IKK complex activity and NF-kappaB activation. Mol Cell Biol 23, 2029-2041.